Belalcazar A, et al. – Researchers tested the hypothesis that ganetespib (Gan) plus carfilzomib (Carf) would elicit potent antitumor activity by modulating complementary homeostatic processes. In preclinical studies of pancreatic cancer, Gan plus Carf had been highlighted as a promising combination with synergistic antiproliferative, apoptotic, and pro–autophagy effects.